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Metachromatic leukodystrophy (MLD) is an inherited demyelinating disease that causes progressive neuro-
logic deterioration, leading to severe motor disability, developmental regression, seizures, blindness, deaf-
ness, and death. The disease presents as a late-infantile, juvenile, or adult form. Hematopoietic stem cell
transplantation has been shown to slow disease progression. The purpose of this longitudinal study was to
evaluate long-term treatment outcomes after unrelated donor umbilical cord blood (UCB) transplantation in
pediatric patients according to disease burden and age at onset (ie, late-infantile versus juvenile). Engraft-
ment, survival, treatment-related toxicity, graft-versus-host disease, neurophysiologic measures, and neu-
rodevelopmental function were assessed. To evaluate whether signal intensity abnormalities on magnetic
resonance imaging (ie, modiﬁed Loes scores) predict post-transplant cognitive and gross motor development,
a general linear mixed model was ﬁt to the data. Twenty-seven patients underwent transplantation after
myeloablative chemotherapy; 24 patients engrafted after the initial transplantation. Seven patients died of
infection, regimen-related toxicity, or disease progression. Twenty patients (6 with late-infantile onset and 14
with juvenile onset) were followed for a median of 5.1 years (range, 2.4 to 14.7). We found that patients with
motor function symptoms at the time of transplant did not improve after transplantation. Brainstem auditory
evoked responses, visual evoked potentials, electroencephalogram, and/or peripheral nerve conduction
velocities stabilized or improved in juvenile patients but continued to worsen in most patients with the late-
infantile presentation. Pretransplant modiﬁed Loes scores were highly correlated with developmental
outcomes and predictive of cognitive and motor function. Children who were asymptomatic at the time of
transplantation beneﬁted most from the procedure. Children with juvenile onset and minimal symptoms
showed stabilization or deterioration of motor skills but maintained cognitive skills. Overall, children with
juvenile onset had better outcomes than those with late-infantile onset. As in other leukodystrophies, early
intervention correlated with optimal outcomes. We conclude that UCB transplantation beneﬁts children with
presymptomatic late-infantile MLD or minimally symptomatic juvenile MLD.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Metachromatic leukodystrophy (MLD) is an inherited
lysosomal storage disorder caused by arylsulfatase A deﬁ-
ciency. This lysosomal enzyme isnecessary for thebreakdown
of cerebroside 3-sulfatase, which accumulates within lyso-
somes of myelin-forming cells in the central and peripheral
nervous system. Sulfatides also accumulatewithin lysosomes
of cells in the liver, kidneys, and gallbladder but to a lesser
extent than in the nervous system. MLD is characterized
clinically by symptoms related to progressive demyelination
and is classiﬁed according to age at onset as late infantile
(6months to4years), early juvenile (4 to6years), late juvenile
(6 to 16 years), or adult (>16 years). Early signs in the late-
infantile and early-juvenile forms include blindness, gait
disturbance, loss of speech, loss of hearing, and quadriparesis.
Older children and adults oftenpresentwith gait disturbance,
mental regression or frontal lobe syndrome, and behavioral
abnormalities. Disease progression results in death withinedgments on page 624.
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13.01.010a few years (for the late-infantile form) to several decades (for
the adult form) [1].
Although hematopoietic stem cell transplantation using
bone marrow or umbilical cord blood (UCB) has been re-
ported to provide some beneﬁt for infants and children with
MLD, its effectiveness in arresting disease progression is
a matter of debate. Some case reports of children with
juvenile MLD who underwent bone marrow transplantation
indicate stabilization of clinical course, cognitive measures,
and neurophysiologic measures [2,3]. However, these results
could be attributed to limited follow-up rather than to
arrested disease progression [4]. In other cases, motor dete-
rioration continued after bone marrow transplantation even
though cognitive decline appeared to be halted [5,6]. In
general, patients with late-infantile or juvenile MLD who
exhibited disease progression at the time of transplantation
have experienced continued deterioration in neurologic
status and/or neurophysiologic measures [7-9]. In the late-
infantile form, deterioration has been reported when trans-
plantation was performed less than 1 year before symptom
onset [5,7,10-12].
UCB transplantation can improve neurologic outcomes
in children with other lysosomal storage diseases, such
as Hurler syndrome and Krabbe disease, as well asTransplantation.
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the course of the disease [13-16]. Thus, we hypothesized that
patients with late-infantile or juvenile MLD who undergo
UCB transplantation early in the disease course might
stabilize or even gain neurodevelopmental function. In this
study, we retrospectively evaluated clinical and functional
outcomes of patients who underwent UCB transplantation at
a single institution.We also evaluatedwhether pretransplant
Loes scores (modiﬁed for MLD) were predictive of post-
transplant cognitive and motor outcomes.
METHODS
Patient Characteristics
We reviewed the medical records of patients with MLD referred to the
Program of Neurodevelopmental Function in Rare Disorders at the Univer-
sity of North Carolina at Chapel Hill between October 4, 1997 and March 1,
2011. The patients were referred for pre- and post-transplant evaluations by
the Pediatric Blood andMarrow Transplantation Program at Duke University
Medical Center. These patients were enrolled in different transplant proto-
cols at Duke University, all of which were approved by the institutional
review board for the time of study. This retrospective studywas approved by
the institutional review board of the University of North Carolina at Chapel
Hill. For all patients, MLD diagnosis was conﬁrmed by arylsulfatase A activity
and presence of urinary sulfatides. Signed parental consent was obtained for
both transplantation and neurodevelopmental follow-up.
Donor Characteristics and Procurement
Cord blood units were obtained from U.S. public banks. The cry-
opreserved units were tested, thawed, and washed before administration as
previously described [14,17]. Cord blood units with the highest nucleated
cell dose, matching at least four of six human leukocyte antigen (HLA) loci,
were tested for arylsulfatase A activity. For each transplant, the unit with the
closest HLA match, highest nucleated cell dose, and normal enzyme activity
was selected. Nine patients were enrolled in the Cord Blood Transplantation
Study (COBLT) (three under the expanded access protocol [COBLT-EAP]) and
previously reported [18].
Conditioning Regimen, Transplantation Procedure, and Supportive Care
All but one patient underwent pretransplant conditioning therapy with
myeloablative chemotherapy consisting of busulfan (16 doses of 20 to 40
mg/m2 per dose to target a steady-state plasma concentration of 600 to 900
ng/mL), cyclophosphamide (200 mg/kg), and horse antithymocyte globulin
(90 mg/kg) [16,18]. Cryopreserved units of cord blood were thawed, washed,
and administered intravenously as previously described [16]. Prophylaxis
against graft-versus-host disease (GVHD) was administered using cyclo-
sporine for 9 months and methylprednisolone or mycophenolic acid for 2 to
3 months as long as GVHD was not active. One patient underwent reduced-
intensity conditioning with alemtuzumab (3.2 mg/kg), ﬂudarabine (150 mg/
m2), melphalan (140 mg/m2), thiotepa (200 mg/m2), and hydroxyurea.
GVHD prophylaxis in this patient consisted of tacrolimus and mycopheno-
late. Supportive care was administered as previously described [16].
Myeloid engraftment was deﬁned as the ﬁrst of 3 consecutive days with
an absolute neutrophil count >500/mm3. Platelet engraftment was deﬁned
as 50,000/mm3 for 7 consecutive days without transfusion support. Donor
chimerism was determined by restriction fragment length polymorphism
analysis of total, þ/elymphoid, and myeloid cells in the peripheral blood at
engraftment, 100 days, 6 months, and 12 months and annually thereafter.
Arylsulfatase A levels were also evaluated at these time points.
Clinical Follow-Up
All patients underwent standard transplant follow-up studiesat 100days,
6 months, and 12 months and annually thereafter. Engraftment, chimerism,
acute and chronic GVHD, and treatment-related morbidity were scored on
these visits. In addition, patients underwent evaluations by multiple
pediatric subspecialists at baseline and every 6 to 12 months thereafter,
including in-depth neurodevelopmental assessment. Serial brain imaging,
neurophysiologic examinations, and neurodevelopmental studies were per-
formed within the same week. Details of these studies are presented below.
Neurodevelopmental Assessment
All patients underwent comprehensive neurodevelopmental examina-
tions at the Program for the Study of Neurodevelopmental Function in Rare
Disorders at the University of North Carolina at Chapel Hill. Follow-up data
were available through December 3, 2012. Standardized and validated
neurobehavioral tools were used to assess all children, and outcomes were
compared with norms of typically developing children [19-25]. Ageequivalents were used to allow comparisons across tests and to determine
the acquisition of developmental skills. Gross and ﬁnemotor skills, cognitive
development, receptive and expressive language, and adaptive behavior
were longitudinally assessed.
Scoring of Magnetic Resonance Imaging Studies
Brain magnetic resonance imaging (MRI) was performed at baseline,
6 months, and 12 months and then annually for all surviving patients. A
single neuroradiologist (blinded to clinical status but not diagnosis) graded
the MRI scans using the Loes scoring system, which was developed for
adrenoleukodystrophy [26]. Atrophy was uncommon in our patient pop-
ulation before transplantation but was an expected treatment outcome;
therefore, atrophy scores were not included in the total score, hereafter
referred to as a modiﬁed Loes score [26].
The reader was aware of patient age, which was needed to assess the
degree of myelination, but no other clinical information. Images of all
patients but one were reviewed on a PACS workstation (Duke University,
Durham, NC), which allowed windowing of images to optimize signal
intensity of structures for scoring and direct correlation of structures in
different imaging planes.
Neurophysiologic Studies
Electroencephalogram (EEG), nerve conduction velocity (NCV), ﬂash
visual evoked potentials (VEPs), and brainstem auditory evoked responses
(BAERs) were assessed before transplantation and at scheduled intervals
thereafter. EEGs were considered abnormal if focal or generalized slowing,
spikes, or sharp waves were present. VEPs were considered abnormal if the
P100 wave was absent or delayed. BAERs were considered abnormal if wave
I to V interpeak latency was prolonged or if any of the obligate wave forms
(I, III, V) were absent. NCVs were considered abnormal if they showed
prolonged distal latency, low amplitude, no evoked response, or prolonged
F-wave latency.
Statistical Analysis
Cumulative incidences of engraftment and GVHD were calculated by
standard methods [27]. The probability of overall survival (patients who are
alive with durable engraftment) was calculated by the Kaplan-Meier
method. The cut-off date for data analysis was June 30, 2012. Descriptive
statistics were used to describe neurophysiologic outcomes. To evaluate
whether the modiﬁed pretransplant Loes score is predictive of post-
transplant cognitive and gross motor development, a general linear mixed
model was ﬁt to the data. Age at evaluation, modiﬁed Loes total score, and
the age  Loes interaction termwere regressed on both cognitive and gross
motor age-equivalent scores.
RESULTS
Patient and Donor Characteristics
Twenty-seven children (.3 to 16.5 years old; boys, n ¼ 18;
girls, n ¼ 9; white, n ¼ 24; Asian Indian, n ¼ 1; African
American, n ¼ 2) underwent transplantation with banked
UCB from unrelated donors after myeloablative chemo-
therapy (Table 1). Ten children had late-infantile-onset MLD
(4 were asymptomatic), and 17 had juvenile-onset MLD
(4 were asymptomatic). Cord blood units were matched at 6/
6 (n ¼ 3), 5/6 (n ¼ 8), or 4/6 (n ¼ 16) HLA loci.
Six patientswere enrolled in the COBLT, 3 in theCOBLT-EAP,
11 in an ongoing single institution study, 1 in the reduced-
intensity conditioning protocol, and the last 6 patients in
an ongoing study of aldehyde dehydrogenaseebright cells.
Median age at transplantation was 5.2 years. The median
nucleated cell dose of units selected for transplantation was
6.54  107 cells/kg. After thawing, the median total nucleated
cell dose administered was 5.19  107 cells/kg (range, 1.49 to
25.77) (Table 1), and the median infused CD34 cell dose was
1.53  105 cells/kg (range, 1.5 to 12.6).
Engraftment and GVHD
The cumulative incidence of neutrophil and platelet
engraftment (50,000/mm3) was 77.8% (95% conﬁdence
interval [CI], 57.0 to 98.6) at day 42 and 77.8% (95% CI, 55.6 to
100) at 1 year. The median time to neutrophil and platelet
engraftmentwas 28 days (range,14 to 76) and 120 days (range,
Table 1
Patient and Graft Characteristics and Outcomes
Patient
No.
Age at
Diagnosis
(yr)
Symptoms Age at
Transplant
(yr)
Loes
Score
HLA
Matches
(No. Total)
Number of Nucleated Cells (107/kg)
Cryopreserved Reinfused Time to
Neutrophil
Engraftment
(Days)
Time to Platelet
Engraftment
(Days)
Chronic
GVHD
Grade
Overall
Survival
(Days)
Juvenile onset: asymptomatic at time of UCB transplantation
7 2.2 A 2.3 3.0 4/6 11.37 8.97 37 NE 59*
8 4.7 A 5.7 2.0 5/6 4.67 4.32 38 109 Ext 766*
9 3.3 A 4.3 2.5 6/6 3.01 3.44 47 129 3193
26 .8 A 1.1 4.0 5/6 14.67 8.41 14 37 Ext 906
Juvenile onset: symptomatic at time of UCB transplantation
10 8.5 S 8.6 15.5 5/6 6.68 5.86 20 113 3054
11 6.6 S 6.7 16.0 4/6 5.38 5.22 25 139 Ext 4075
12 7.7 S 7.9 18.5 4/6 5.08 4.99 62 199 2878
13 7.3 S 7.4 18.0 4/6 8.38 6.33 NE NE 278*
14 16.1 S 16.5 4/6 2.28 1.49 25 146 5383
15 6.4 S 6.5 15.0 4/6 8.09 5.50 19 57 1934
18 13.9 S 14.0 13.0 4/6 6.44 5.21 24 53 1703
19 6.0 S 6.2 15.0 4/6 6.49 4.07 36 105 1708
20 6.9 S 7.0 15.0 4/6 4.69 3.52 38 99 Lim 1507
21 4.9 S 5.1 12.0 4/6 9.31 6.85 14 39 1352
22 6.3 S 6.5 14.0 5/6 4.39 3.19 28 77 1324
25 6.5 A 6.8 5/6 6.54 4.58 24 37 907
27 8.4 S 9.0 4/6 5.04 3.53 24 124 891
Median 6.8 6.6 15.0 5.91 4.79 25.0 105.0 1507
Late-infantile onset: asymptomatic at time of UCB transplantation
1 .0 A .1/2.8y 5.0 5/6 16.42 12.60 40 164 Lim 2852
2 .8 A 1.2 3.0 5/6 5.70 24 193 Ext 2647
23 .5 A .7 .0 6/6 16.94 9.02 31 120 285*
24 .0 A .3 1.0 5/6 25.77 12.70 28 88 Lim 1010
Late-infantile onset: symptomatic at time of UCB transplantation
3 1.9 S 2.0 14.5 4/6 4.67 3.35 76 NE 173*
4 1.9 S 2.4 15.0 4/6 15.43 3.96 50 379 3818
5 3.9 S 5.3 10.0 4/6 5.22 3.84 51 NA 88*
6 3.2 S 3.6 4/6 6.04 5.14 33 NE 99*
16 2.0 S 2.2 6.0 6/6 7.15 6.34 24 48 1849
17 3.0 S 3.2 11.0 4/6 7.96 6.76 18 63 1858
Median 1.9 2.3 5.5 7.96 6.02 32.0 120.0 1429.5
A indicates asymptomatic at time of treatment; S, symptomatic at the time of treatment; Ext, extensive; Lim, limited to skin involvement; NA, not available;
NE, no engraftment.
* Deceased.
y Transplanted twice.
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patient experienced autologous recovery after his ﬁrst trans-
plantation and underwent a second transplantation with ﬂu-
darabine, cyclophosphamide, and Campath conditioning, but
again experienced autologous reconstitution. A second patient
experienced late graft failure 31 months after transplantation
and after a drug error in which cytosine arabinoside was
administered instead of an antiviral medication; retrans-
plantation with T celledepleted haploidentical bone marrow
resulted in full engraftment. A third patient experienced graft
rejection and died shortly after transplantation.
The cumulative incidence of acute GVHD grades II to IV at
day 100 was 40.7% (95% CI, 22.6 to 58.8), and the cumulative
incidence of chronic GVHD at 24 months was 25.9% (95% CI,
9.3 to 42.5). Twenty children had acute GVHD (grade I, n ¼ 8;
grade II, n ¼ 11; grade III, n ¼ 1), and 3 patients died before
evaluation for GVHD. Four of seven children with chronic
GVHD had extensive GVHD and three had only skin involve-
ment (Table 1). All patientswhoengraftedhadenzymewithin
the normal range.
Morbidity and Survival
At the time of this writing, 20 of 27 patients are surviving,
with a long-term (5-year) survival probability of 74.1% (95%
CI, 53.2% to 86.7%); median follow-up for patients who
survived was 5.1 years (range, 2.4 to 14.7) (Figure 1). Sevenchildren died after transplantation (four late-infantile onset,
three juvenile onset) (Table 2). The late-infantile group had
a 5-year survival probability of 60.0% (95% CI, 25.3% to 82.7%),
whereas the juvenile group had a 5-year survival probability
of 82.4% (95% CI, 54.7% to 93.9%). Signiﬁcant disease
progressionwas noted in 10 patients (6 late-infantile onset, 4
juvenile onset). Other complications after transplantation
included failure to engraft (n ¼ 1) and mixed chimerism
(n ¼ 1) (Table 3).Neurologic Outcomes
Brain MRI scans
MRI scans were available for 24 patients before trans-
plantation and 21 patients after transplantation. The pre-
transplant modiﬁed Loes scores indicated baseline MRI
abnormalities for all children except two asymptomatic
patients diagnosed because of a family history. Median Loes
scores were 14.5 for late-infantile MLD and 5.5 for juvenile
MLD, indicating more severe central nervous system
impairment for patients with late-infantile onset. Sixteen of
19 children who had both pre- and post-transplant modiﬁed
Loes scores showed improvement after transplantation.
Lower pretransplant Loes scores were associated with
greater developmental gains in both cognitive skills (late
infantile, r ¼ .72; P ¼ .10; juvenile, r ¼ .68; P ¼ .022) and
Figure 1. Overall survival of all patients (A) and according to age at onset (B) through the follow-up period.
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r ¼ .88; P ¼ <.001) (Figure 2).
Neurophysiology studies
In the late-infantile-onset group, VEP results were normal
for 9 of 10 patients tested and remained normal after
transplantation for all 5 patients tested during follow-up. In
the juvenile-onset group, pretransplant VEP results were
normal for 10 of 13 patients tested and remained normal for
8 patients after transplantation. In addition, two of three
juvenile-onset patients with abnormal pre-transplant results
had normal post-transplant results (Table 4).
In the late-infantile-onset group, pretransplant BAER
results were abnormal for all 10 patients and remained
abnormal after transplantation for the 6 patients tested
during follow-up. In the juvenile-onset group, pretransplant
results were abnormal for 14 of 15 patients tested and
remained abnormal after transplantation. One asymptomatic
patient had normal pretransplant results, which remained
normal after transplantation. Interestingly, his sibling, who
was symptomatic at transplantation and who was tested
only after treatment, also had normal BAER results.
In the late-infantile-onset group, pretransplant NCV
results were abnormal for eight of nine patients tested and
remained abnormal for the six who were tested after trans-
plantation (four worsened and two stabilized). OneTable 2
Mortality of Patients with MLD Who Underwent Transplantation
Cause of Death (Infection, Toxicity,
Disease Progression)
Number of Patients
(n ¼ 7)
Multiple organ failure 1
Respiratory failure (after chronic lung disease) 2
Viral infections/malignancy 3
Epstein-Barr PTLD (1)
Disease progression and infection 1
PTLD indicates post-transplant lymphoproliferative disorder.minimally symptomatic patient had normal pretransplant
results but showed abnormal results 3 months after trans-
plantation. In the juvenile-onset group, pretransplant results
were abnormal for 12 of 14 patients tested. Of the 12 who
were abnormal, 11 had available post-transplant results, and
10 of this 11 remained abnormal (including 3 who wors-
ened). Of the two juvenile-onset patients who were normal
at baseline, one became abnormal after transplantation.
In the late-infantile-onset group, 5 of 10 patients had
normal pretransplant EEG results. Of the seven for whom
post-transplant results were available, one was normal after
transplantation, two showed seizure activity, and four
showed diffuse generalized slowing. In the juvenile-onset
group, 8 of the 14 tested had normal pretransplant EEG
results. Five of the 16 tested after transplantation remained
normal. Of the 11 whowere abnormal, 7 showed only diffuse
slowing and 4 showed diffuse slowing with voltage asym-
metry or spikes (3 had seizure activity). Most seizures
manifested as staring episodes. Although EEG recordings
showed epileptiform activity for three patients, only one
developed clinical seizures.
Neurodevelopmental function
Cognitive function. In the late-infantile-onset group, the
patient treated as an asymptomatic 3-month-old infantTable 3
Morbidity of Patients with MLD Who Underwent Transplantation
Complication Number of Patients
Pericardial effusion 3
Pneumatosis intestinalis 3
Subdural effusion 2
Cholestatic disease requiring cholecystectomy 4
Neurologic disease progression 10
Aspiration (4)
Seizures (1)
Respiratory failure (tracheostomy) 1
Figure 2. Gross motor and cognitive function versus Loes score. (A) Cognitive function and (B) gross motor at the last evaluation (ratio of functional age-to-
chronologic age) are plotted against pretransplant modiﬁed Loes scores. Patients are represented by red markers (late-infantile-onset MLD) and blue markers
(juvenile-onset MLD). Red and blue lines indicate the least-squares regression lines for each group. Symptom status at the time of transplantation is indicated by
hollow markers (asymptomatic) versus solid markers (symptomatic).
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The patient treated at 14 months, when he was cognitively
normal but had mild motor impairment, maintained skills at
a 14-month-old level through 6 years of age and did not have
further deterioration. The patient treated as a newborn
developed normally until the graft failed after a toxic insult at
15months of age. After his second transplant, he continued to
gain cognitive skills until 4 years of age when development
reached a plateau. All patients who exhibited cognitive
impairment at baseline experienced a rapid decline (n ¼ 4).
Three patients died before the post-transplant evaluations.
In the juvenile-onset group, ﬁve patients who were
cognitively normal at baseline have continued to gain skills at
a normal rate, except for one who died from transplantation-
related complications. Five patients with borderline or
delayed cognitive skills at baseline have continued to gain
cognitive skills, but two have reached a plateau. Four patients
declined rapidly, and three died before follow-up.
Gross motor function. In the late-infantile-onset group, the
neonatal patient gained gross motor skills at an appropriate
rate but experienced a loss of motor skills after the second
transplant, followed by a plateau. The patient transplanted at
3 months showed a mild delay in motor development 14
months after transplantation. The patient transplanted at 14
months with minimal motor symptoms experienced a loss of
motor skills and is not able to walk independently. The
remaining patients are severely delayed and cannot
ambulate.
In the juvenile-onset group, patients who were asymp-
tomatic at transplantation have borderline motor function.
One patient who showed mild motor impairment before
transplantation is gaining skills at a normal rate and func-
tions at the low-normal level. Two continue to gain skills and
are in the borderline range, two exhibited mild deterioration
but subsequently stabilized, seven lost most of their motor
function (four of whom can sit up), three died, and two were
lost to follow-up. Of the 12 patients with juvenile-onset
disease, 4 patients can walk independently, 1 uses a walker,3 are wheelchair-dependent for most of the day, and 4 are
nonambulatory.
Fine motor function. Of the surviving patients with late-
infantile onset who were asymptomatic at baseline, one is
developing normally, but the other two reached a develop-
mental plateau at approximately 2 years of age. Four of ﬁve
symptomatic patients had extreme loss of function. The
other patient stabilized at the pretransplant level.
Of the three asymptomatic juvenile-onset patients, two
who were assessed post-transplant are developing normally.
Of the six symptomatic patients who underwent post-
transplant evaluations, four show signiﬁcant deterioration
in ﬁne motor development, one stabilized, and one showed
gains.
Adaptive behavior
Adaptive behavior is a standardized measure of inde-
pendent and self-help skills based on parents’ perceptions of
their childs’ abilities. All areas of development contribute to
adaptive behavior. Because of the marked degree of motor
involvement, many skills were affected in the study group. In
the late-infantile-onset group, patients who were asymp-
tomatic at the time of transplantation stabilized at the pre-
transplant level, but the symptomatic patients continued to
decline. In symptomatic patients, adaptive behavior followed
the same course as gross motor development.
In the juvenile-onset group, two of four asymptomatic
patients made appropriate gains and two died. One died
before the post-transplant evaluation could be completed. Of
the 13 symptomatic children, 5 showed a rapid decline in
adaptive behavior, 2 stabilized at their pretransplant level,
and 3 showed initial decline with later improvement or
stabilization. Two patients died before post-transplant eval-
uation, and no data are available for one patient.
Language
In the late-infantile-onset group, one patient who was
asymptomatic at baseline shows normal language
Table 4
Neurophysiologic Measures at Baseline and Last Examination
Patient No. Baseline BAERs Last BAERs Baseline EEG Last EEG Baseline NCV Last NCV Baseline VEP Last VEP
Juvenile onset: asymptomatic at time of UCB transplantation
7 A A N A N N A N
8 A A N N A A N N
9 A A N N A A N N
26 N N N N A N N N
Juvenile onset: symptomatic at time of UCB transplantation
10 A A N A A d A N
11 A A A A A A d d
12 A A N A A A A A
13 A A A A A A N A
14 d d A d d A d d
15 A d A A A d N
18 A A N N N A N N
19 A A A A A N d
20 A A A A A A N N
21 A A N N A A N N
22 A A A A d A N N
25 d N A d N d A
27 A A A A A A N N
Late-infantile onset: Asymptomatic at time of UCB transplantation
1 A A N A A A N N
2 A A N A N A N N
23 A A N A A A N N
24 A A N N A A N N
Late-infantile onset: symptomatic at time of UCB transplantation
3 A d A A A d N d
4 A d A d A A N d
5 A d A d A d N d
6 A d A A d N d
16 A A A A d d N N
17 A A N A A A A d
A indicates abnormal; N, normal.
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normal range. Four of ﬁve symptomatic patients are severely
impaired, and one gained skills but now functions at the level
of a 12-month-old child.
In the 15 juvenile-onset patients assessed, 3 asymptom-
atic patients continued to gain skills. Three symptomatic
patients show language development in the normal range,
one stabilized at pretransplant levels, and ﬁve experienced
rapid decline and are severely impaired. Three patients did
not undergo post-transplant evaluation.
Comparative developmental trajectories
In the late-infantile group, the motor area was signiﬁ-
cantly more affected than any other area of development and
showed no improvement over time. Cognitive and language
developed similarly, showing gains but eventual plateauing.
Adaptive and ﬁne motor skills fall between language/cogni-
tive and gross motor development (Figure 4).
For the juvenile group, all areas of development show
improvement, with cognitive and language development
being the strongest and gross motor development the
weakest. Adaptive and ﬁne motor development are similarly
affected and fall between language/cognitive and gross
motor development (Figure 4). This proﬁle characterizes the
phenotype of transplanted patients with MLD.
DISCUSSION
In this study we evaluated the overall survival, engraft-
ment, and neurodevelopmental outcomes of 10 patients
with late-infantile-onset MLD and 17 patients with juvenile-
onset MLD who underwent UCB transplantation from
unrelated donors after myeloablative chemotherapy. The
feasibility, safety, and efﬁcacy of UCB transplantation weresimilar to ﬁndings of previous studies [16,18]. Family history
permitted the early diagnosis and treatment of eight children
before the onset of clinical symptoms (four with juvenile
onset, four with late-infantile onset). This is one of the few
published comprehensive longitudinal studies of a large
group of patients with various forms of MLDwho underwent
transplantation in a single institution. After serial neuro-
physiologic, neuroradiologic, and neurodevelopmental
evaluations performed within a week of each other using
standardized protocols, these patients were evaluated for
a median follow-up of 5.1 years (range, 2.4 to 14.7).
UCB transplantation successfully replaced the missing
enzyme and stabilized disease in patients who were
asymptomatic at the time of transplantation, regardless of
age at onset. However, children with moderate to severe
symptoms did not beneﬁt from transplantation, and seven
patients in this group died. In the late-infantile-onset group,
only asymptomatic patients with minimal disease burden
beneﬁted from transplantation. However, because peripheral
neuropathy is severe even at 3 months of age, secondary
muscle weakness affected motor skill development.
The modiﬁed Loes scores were useful in deﬁning disease
severity and showed that demyelination was greater in
patients with late-infantile onset than in patients with
juvenile onset. After transplant, Loes scores improved,
showing fewer areas of demyelination and new areas of
myelination. Although this was not compared with normal
myelin development, the Loes scores improvement indicates
fewer areas of increased intensity signal on T2 images. In our
group of patients, those with Loes scores 5 derived greater
beneﬁt from transplantation. However, we do not recom-
mend that Loes scores alone be used to guide treatment
decisions. Other variables must also be considered, such as
Figure 3. Developmental outcomes are shown by plotting age-equivalent score (developmental age) against actual age (calendar age) for late-infantile and juvenile
patients. (A) Cognitive and (B) gross motor development for the late-infantile group. (C) Cognitive and (D) gross motor development for the juvenile group. Red and
blue lines indicate individual values of children who were symptomatic (red) and asymptomatic (blue) at time of transplantation. Gray lines represent the mean and
approximate variability (95% CI) observed in typically developing children.
H.R. Martin et al. / Biol Blood Marrow Transplant 19 (2013) 616e624622the degree of peripheral neuropathy, which can be severe
even in very young asymptomatic patients.
We found that gross motor abilities were greatly affected
by peripheral neuropathy. Patients who had normal gross
motor skills before transplantation also had normal NCV
results. All patients with late-infantile onset and most
patients with juvenile onset who underwent post-transplantevaluations had abnormal NCV results after treatment, and all
but one patient exhibited a decline in gross motor function.
Factors contributing to this decline may include disease
progression during the period between transplantation and
engraftment, muscle weakness due to corticosteroid use,
prolonged inactivity, and neurotoxic effects of chemotherapy.
It is alsopossible that transplantation fails to correct disease in
Figure 4. The average developmental trajectory for each developmental domain is presented for the patients who were asymptomatic at the time of transplantation.
Developmental outcomes for each developmental domain are shown by plotting age-equivalent score (developmental age) against actual age (calendar age).
(A) Developmental trajectories for late-infantile onset. (B) Developmental trajectories for juvenile onset. Gray lines represent the mean and approximate variability
(95% CI) observed in typically developing children.
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ered to the peripheral nerves.
In this study, the ﬁrst physiologic test to detect abnor-
malities was the BAER test, followed by NCV studies. Changes
on brainMRI scans and generalized slowing on EEG appeared
later. Clinical seizures were evident in only one patient. VEP
results were normal until late in the disease progression. In
some patients with juvenile onset, VEP results normalized
after transplantation.
In general, gross motor function was more severely
affected and responded less well to treatment. Gross
motor skills fell considerably below patient’s cognitive
abilities, adversely affecting adaptive behavior. Seven of 12
patients with juvenile onset who were followed long term
showed normal language development. Unlike Krabbe
disease, where cognitive and expressive language scores
are lower than receptive language, in MLD cognitive skills
and receptive and expressive language have similar
trajectories. It is possible that receptive language is
more affected in MLD because of the increased BAER
abnormalities.
In our group of patients with late-infantile MLD we were
able to evaluate transplantation outcomes for only three
asymptomatic patients (one neonate, one 3-month-old
infant, and one 14-month-old child). Unfortunately, the
neonatal patient experienced toxic and an anoxic insult
unrelated to his initial transplant, which limits the inter-
pretation of his data. Despite this complication, his cognitive
abilities continue to develop, but he is wheelchair-
dependent. The patient who was treated at 3 months of
age and was followed for 31 months has normal cognitive
function but severe peripheral neuropathy and lower
extremity weakness that interfere with her ability to walk
independently. Nonetheless, rapid disease progression was
expected at 13 months of age based on family history.
The patient treated at 14 months who underwenttransplantation when minimally symptomatic now has
severe motor involvement and is wheelchair-dependent. His
cognitive abilities at 6 years are delayed but are higher than
his two older untreated siblings at the same age. The
remaining patients with late-infantile-onset MLD were
more severely affected at the time of transplantation and
showed disease progression. Although outcomes of
asymptomatic patients are signiﬁcantly better than those of
their siblings, the four asymptomatic patients with late-
infantile onset showed early signs of peripheral neurop-
athy, which did not improve in the three who had follow-up
studies. The effect of transplantation was better character-
ized in patients with juvenile onset because only 2 of 17
patients died before follow-up evaluations. However, addi-
tional follow-up is necessary because of the lack of natural
history studies and the slower disease progression seen in
patients with juvenile-onset MLD. Given the scarcity of
patients treated while minimally symptomatic, collabora-
tion among centers using standardized protocols is needed.
To predict treatment beneﬁts for an individual patient, the
following may also be needed: MRI techniques that quantify
brain damage, a closer look at the degree of peripheral
neuropathy, a better understanding of the signiﬁcance of
certain mutations, and/or identiﬁcation of biomarkers that
reﬂect disease severity.
Only long-term follow-up of patients who are asymp-
tomatic at transplantation will clarify whether neurologic
disease progression can be halted or merely slowed by UCB
transplantation. This study shows that early severe periph-
eral nerve damage occurs even before symptoms are
apparent. Although improvements of the central nervous
systemwere observed, peripheral neuropathy was either too
advanced to be reversed or is not affected by transplantation.
Newborn screening is needed to identify the patients likely
to beneﬁt most from transplantation and other future
therapies.
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